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Summary: A randomized concentration-controlled clinical trial (RCCCT) is an 
alternate experimental design to the standard dose-controlled study. In a 
RCCCT. patients are randomly assigned to predefined plasma or blood drug 
concentrauon ranges !low. medium. and high). With the caveat that concen-
tration ranges are sufficiently separated. this design should enhance the ability 
to discover important concentration response relationships. FK-506. a potent 
and promising immunosuppressive agent for prevention and treatment of graft 
rejection. has shown significant clinical activity in some immune-mediated 
disorders. To implement the RCCCT design. a novel FK-506 intelligent dosing 
system (IDS) was used to guide all doses to prospectively achieve the target 
concentration range specified in the study protocol. Patients enrolled in these 
trials suffered from a variety of autoimmune disorders. including mUltiple scle-
rosis. primary biliary cirrhosis. psoriasis. autoimmune chronic active hepatitis. 
and nephrotic syndrome. We observed excellent predictive performance of the 
IDS for all patients. The accuracy (mean prediction error) of the IDS was 
- 0.022 ng:ml and the precision (standard deviation of the prediction error) was 
0.119 ng/m1. Thus. the IDS is both accurate and reproducible for autoimmune 
patients. We conclude that the RCCCT design. guided by an accurate and 
precise IDS. is an informative and cost-effective approach for evaluation of 
efficacy and safety of effective but highly toxic agents. Key Words: Concen-
tration-controlled artiticial intelligence-Dynamic dosing-Autoimmune dis-
eases. 
I n late 1991. we began randomized concentration-
controlled clinical trials (RCCCTs) designed to 
evaluate the efficacy and toxicity of FK-506 in cer-
tain autoimmune diseases being studied at the Uni-
versity of Pittsburgh Medical Center (UPMC) (Ta-
ble I). Concentration-controlled trials (CCTs) were 
wnsidered the best choice tor evaluating FK-506 
because of the narrow therapeutic index of FK-506 
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as well as the considerable sample size advantages 
that CCTs offer over standard trial designs (I). Sub-
stantially smaller sample sizes can be used when 
conducting CCTs since CCTs. by design. minimize 
interindividual drug level variability within compar-
ison groups and. consequently. decrease within-
group clinical variability. This design will facilitate 
early assessment of efficacy. while prOViding infor-
mation on concentration (dose) response. Another 
reason we found CCTs very attractive was that this 
pilot trial design does not necessitate a placebo 
group. which we believed would be unethical for 
many of the diseases we wished to study. 
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TABLE 1. Autoimmune diseases 
Rheumatology 
Systemic sclerosis 
Polymyositis dermatomyositis 
Rheumatoid arthritis 
Systemic lupus 
Systemic vasculitides 
8eh<;et's disease 
Ophthalmology 
Uveitis 
Episcleritis 
Retinitis 
Gastroenterology 
Autoimmune chronic active hepatitis 
Inflammatory bowel disease 
Primary biliary cirrhosis 
Primary sclerosing cholangitis 
Sprue 
Neurology 
Multiple sclerosis 
Chronic inflammatory demyelinating polyneuropathy 
Autoimmune inner ear disease 
Endocrinology 
Type I diabetes mellitus 
Nephrology 
Nephrotic syndrome 
Glomerulonephritis 
Dermatology 
Alopecia areata totalis and universalis 
Pyoderma gangrenosum 
Severe psoriasis 
Epidermolysis bullosa 
METHODS 
Approximately 300 patients meeting the specific 
entry criteria for the protocol in which they were 
enrolled were randomized to either a high. medium. 
or low FK-506 plasma concentration range using a 
block randomization design for three groups. This 
allocation design ensures that an equal number of 
ratients will be in anyone of the treatment groups 
at any point in time. Randomization was carried out 
hy sequential draw of assignment. and the three 
block sizes used were selected randomly with equal 
rrobability. The order of assignment within a block 
was determined by generating a random number be-
tween 0 and I and then rearranging the random 
numbers in ascending order. for these studies. the 
low average plasma concentration of FK-506 was 
targeted at O.:! ng/ml. with a range from 0.1 to 0.4 
ng/ml. The intermediate average concentration was 
targeted at ll.6 nglml. with a range from OA 10 ll.H. 
and the high average plasma concentration target 
was 1.0 nglml. with a range from lUI to 1.2 ng/ml. 
This approach substitutes for a preconceived mgi 
kg/day dosing scheme. which may he completelv 
inappropriate for a given patIent (Fig. I), The start-
ing oral dose regImen of FK-506 was usually 0.075 
mg/kg/day in divided doses given every 12 h. In the 
interest of patient safety and compliance. all pa-
tients enrolled in these studies were prerandom-
ized. kept in the low FK-506 plasma concentration 
range of 0.1-0.4 ng/ml until they were stable. and 
then moved to the zone to which they had been 
randomized. Failure of a patient to achieve or be 
maintained within his/her randomized zone was 
considered a treatment failure. To determine the 
FK-506 dosage required to achieve the desired tar-
get plasma concentration. an artificial intelligence 
dosing system (IDS). which would predict drug dos-
ages and concentrations. was developed. To use 
this dosing system. the physician enters the pa-
tient's current FK-506 dose (mg/day). the patient's 
current plasma concentration (ng/mD. and the target 
plasma concentration (ng/mll. The IDS then calcu-
lates the FK-506 dose required to achieve target 
concentration. 
In a CCT. patients are assigned to predetermined 
average plasma drug concentration ranges using an 
individualized dosing scheme. Simple linear regres-
sion is used to test the null hypothesis that the mean 
change in efficacy and toxicity parameters (for con-
tinuous variables) is not linearly related to FK-506 
target plasma concentration. The XC test of associ-
ation was used to test whether there is an associa-
tion between the rate of nephrotoxicity at pre-
defined time points and FK-506 plasma concentra-
tion. 
Criteria for reducing a patient's FK-506 blood 
plasma concentration range included increase in the 
creatinine concentration of 150% above baseline. 
reduction in the creatinine clearance to <40 cc/min. 
\cvere neurotoxicity (as detined by tremors. sleep 
disturbances and seizures I. and development of 
new onset insulin-dependent diabetes. 
It was left to the discretion of the treating physi-
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cian whether a patient should remain in his/her ran-
domized zone. should that concentration of FK-S06 
not appear to be influencing the patient's disease 
state. If this occurred. the patient would be moved 
to the next zone and treated: however. he/she 
would be recorded as a treatment failure at the orig-
inal zone to which he/she was randomized (intent to 
treat analysis). 
FK-S06 concentration in plasma was measured 
by enzyme-linked immunoabsorbent assay 
(ELISA), using a monoclonal antibody as previ-
ously described (2,3). The coefficient of variation of 
this assay was 17% at 1.4 ng/ml, 14.4% at 2.9 ng/ml. 
and 12% at 5.7 ng/ml. The effective therapeutic 
range for FK-S06 was estimated to be 0.S-2.0 ng/ml 
in transplant patients. and is currently still being 
defined in patients with autoimmune disorders. The 
UPMC currently measures FK-S06 in both plasma 
and whole blood. and predictive models have been 
developed for both matrices. Fujisawa is still deter-
mining which matrix is best for monitoring FK-S06. 
(Fujisawa Corporation. Deerfield. IL. unpublished 
data). 
RESULTS 
To validate our IDS. a prospective study was 
conducted at UPMC (4). Our patient population 
consisted of 32 adult liver (n = 17) and kidney (n = 
IS) transplant patients. Predictions of patient 
plasma concentrations were made throughout their 
clinical courses. Performance of the IDS was as-
sessed using a standard prediction analysis. The 
mean prediction error( MPE). which is calculated as 
the mean difference between the observed and the 
predicted target values. was calculated to be 0.016 
ng/ml. The root mean squared prediction error 
(RMSPE). which is calculated as the standard de-
viation of the prediction errors. was 0.189 ng/ml. 
The 95% confidence interval (Cll for the mean pre-
diction error was calculated to be between - 0.084 
and 0.052. This brackets our calculated accuracy 
(including zero), indicating there is little or no bias 
in the system's dosing predictions. 
In 50- predictions of concentrations made in the 
autoimmune disease patient group. the M PE was 
calculated to be - lI.022 nglml. the RMSPE was cal-
culated to be 0.119 nglml. and the 95%- CI was cal-
culated to be between 0.011 and - 0.055 (Fig. 2). 
These results. as tabulated in Table 2. demonstrate 
the accuracv and preCIsion of this IDS and the util-
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FIG. 2. Autoimmune disease patients: observed versus pre-
dicted FK-506 concentrations. The close correlation between the 
observed and predicted concentrations using the IDS, 
ity of the system to move a patient to a desired 
concentration level and maintain that level. 
DISCUSSION 
The use of CCTs has been very effective in our 
early pilot studies to assess the efficacy and safety 
of FK-S06 in autoimmune disorders. Using this 
study design, our final analysis will provide infor-
mation about the toxic properties of FK-506 as it 
relates to plasma concentration. We will also have a 
relatively rapid. clear picture of the efficacy of FK-
506 in each of the autoimmune diseases studied and 
whether there is a relationship to plasma concentra-
tion. The use of the IDS has been very effective in 
providing physicians a simple method by which 
study patients can be taken to a desired plasma con-
centration and held there. This will simplify our 
analysis by providing clearly defined groups of 
stud v patients where statistical significance can be 
asce~tained for any of the parameters being exam-
ined. Because using this IDS does not require any 
previous computer experience and i~ is user 
friendlv. it will help minimize the learmng curve 
associ~ted with dosing new agents. e.g., FK-506. 
with its large pharmacokinetic variability and nar-
row therapeutic index. The IDS is ideally suited for 
multicenter trials since it would standardize therapy 
and aid in producing reliable homogenous results. 
independent of the study site. 
TABLE 2. ,J.utoimmuf/t' cii.I'l'lISt' rliflentJ' ;one statistics 
\-tean 
Zone .:oncentrallon SD :"IJo. 
Low n.27 n.l:! 10 
\-tedium 0.66 0.16 10 
High I.O!! n.19 10 
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